Euthymics is developing products for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and, under a collaboration with the government, alcohol use disorder (AUD). According to the National Institutes of Health, MDD affects over 15 million American adults. According to the National Institute of Alcohol Abuse and Alcoholism (NIAAA), approximately 18 million Americans have alcohol use disorder (either alcohol dependence or alcohol abuse).
Serotonin, norepinephrine, and dopamine are three important neurotransmitters found in the brain and are associated with mood, focus, cognition and pleasure. Amitifadine is most active toward the inhibition of serotonin reuptake, half as active toward norepinephrine reuptake and only one-eighth as active toward inhibition of dopamine reuptake.
Euthymics Bioscience’s amitifadine is a serotonin-preferring triple reuptake inhibitor being evaluated for MDD in patients failing to respond adequately to an initial course of antidepressant therapy.
Amitifadine is also being evaluated for alcohol use disorder in a government-sponsored collaboration.
Euthymics, located in Cambridge, Massachusetts, is a privately held company. Euthymics Bioscience has been funded in a $28M series A venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB) and Timothy J. Barberich. Key members of the leadership team are experienced drug developers and have been involved in developing several of the most successful neuroscience medications.